

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	29 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-														
Date of change	5 December 2022														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>6,374,769</td><td>9,892,030</td></tr><tr><td>Indirect</td><td>350,000</td><td>-</td></tr><tr><td>Total</td><td>6,724,769</td><td>9,892,030</td></tr></table>				Shares	Options	Direct	6,374,769	9,892,030	Indirect	350,000	-	Total	6,724,769	9,892,030
	Shares	Options													
Direct	6,374,769	9,892,030													
Indirect	350,000	-													
Total	6,724,769	9,892,030													
Class	Unlisted Options.														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>12,505,088</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>12,505,088</td></tr></table>				Shares	Options	Direct	-	12,505,088	Indirect	-	-	Total	-	12,505,088
	Shares	Options													
Direct	-	12,505,088													
Indirect	-	-													
Total	-	12,505,088													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash, see ‘nature of change’ below.		
No. of securities held after change		Shares	Options
	Direct	6,374,769	22,397,118
	Indirect	350,000	-
	Total	6,724,769	22,397,118
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved by Radiopharm Theranostics shareholders at the Annual General Meeting held on 16 November 2022.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.